Ligand Pharmaceuticals (LGNDZ) Loans and Notes Receivables (2016 - 2018)
Ligand Pharmaceuticals (LGNDZ) has disclosed Loans and Notes Receivables for 4 consecutive years, with $3.9 million as the latest value for Q1 2018.
- Quarterly Loans and Notes Receivables changed N/A to $3.9 million in Q1 2018 from the year-ago period, while the trailing twelve-month figure was $3.9 million through Mar 2018, changed N/A year-over-year, with the annual reading at $3.9 million for FY2017, 20.89% up from the prior year.
- Loans and Notes Receivables hit $3.9 million in Q1 2018 for Ligand Pharmaceuticals, roughly flat from $3.9 million in the prior quarter.
- In the past five years, Loans and Notes Receivables ranged from a high of $5.5 million in Q2 2015 to a low of $3.0 million in Q3 2017.
- Historically, Loans and Notes Receivables has averaged $4.1 million across 4 years, with a median of $3.9 million in 2017.
- Biggest five-year swings in Loans and Notes Receivables: crashed 42.18% in 2016 and later increased 20.89% in 2017.
- Year by year, Loans and Notes Receivables stood at $4.8 million in 2015, then plummeted by 32.94% to $3.2 million in 2016, then rose by 20.89% to $3.9 million in 2017, then changed by 0.0% to $3.9 million in 2018.
- Business Quant data shows Loans and Notes Receivables for LGNDZ at $3.9 million in Q1 2018, $3.9 million in Q4 2017, and $3.0 million in Q3 2017.